(RTTNews) - Bio-Techne (TECH), a life science company, on Friday announced the launch of a new line of AI-engineered designer proteins aimed at advancing cell therapy and regenerative medicine. The ...
Partnership strengthens Bio-Techne's (TECH) leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics ...
MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using advanced ...
Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our ...
InvestorsHub on MSN
Bio-Techne tops forecasts as adjusted EPS climbs 10%
Bio-Techne Corporation (NASDAQ:TECH) reported second-quarter fiscal 2026 results that showed steady revenue but stronger ...
Bio-Techne expands 3D stem cell and organoid culture portfolio with a fully defined synthetic alternative: Minneapolis Tuesday, February 3, 2026, 17:00 Hrs [IST] Bio-Techne Corpor ...
Visualizes functional protein-protein interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein proximity, RNA, and proteins on the same tissue ...
Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development. The Minneapolis, ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
Bio-Techne (NASDAQ:TECH) reported second-quarter fiscal 2026 results that management said were largely in line with internal expectations, as strength from large pharmaceutical customers was offset by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results